OncoMatch/Clinical Trials/NCT04068597
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Is NCT04068597 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for haematological malignancy.
Treatment: CCS1477 · Pomalidomide · Dexamethasone · Azacitidine · Venetoclax · Bortezomib · Ixazomib · Elranatamab · Teclistamab · Lenalidomide · Daratumumab — A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard therapy
Must have previously received standard therapy
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory Winship Cancer Institute · Atlanta, Georgia
- Community Health Network · Indianapolis, Indiana
- The Center for Cancer and Blood Disorders (CCBD) · Bethesda, Maryland
- Nebraska Cancer Specialists · Omaha, Nebraska
- University of Nebraska Medical Center · Omaha, Nebraska
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04068597 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify